Search

Displaying results 141 - 150 of 2435 in total
  1. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. … [A11377] Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Human immunoglobulin G

    go.drugbank.com/drugs/DB00028
    ApprovedInvestigational

    Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and io...

    Products: INTRAGAM P, BERIGLOBINA - P
  3. Drug

    Sodium bicarbonate

    go.drugbank.com/drugs/DB01390
    ApprovedInvestigational

    Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

  4. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic

  5. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  6. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

  7. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.

    Synonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2bCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors
  8. Drug

    Diphenhydramine

    go.drugbank.com/drugs/DB01075
    ApprovedInvestigational

    Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes ...

    Mixtures: ConRx PM, ZoDen PDCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  9. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  10. Drug

    Betamethasone

    go.drugbank.com/drugs/DB00443
    ApprovedInvestigationalVet approved

    Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states inclu...

    Mixtures: Betamethasone Combo 6mg/mL PF, Betamethasone Combo 6mg/mL PFCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates